がん抗体薬物複合体の世界市場：市場の機会、特許、価格、承認薬販売と臨床試験動向（2031年）

がん抗体薬物複合体の世界市場：市場の機会、特許、価格、承認薬販売と臨床試験動向（2031年）レポート結果およびハイライト

• 世界のがん抗体薬物複合体市場機会：2031年までに700億米ドル超
• 世界および地域の市場規模に関する洞察（年次および四半期）：2020年から2025年上半期まで
• がん抗体薬物複合体の世界市場予測：2026年から2031年まで
• 承認済みがん抗体薬物複合体の数：>20種類以上の抗体薬物複合体
• 承認済みがん抗体薬物複合体の売上高インサイト：2020年～2025年
• 承認済みがん抗体薬物複合体の特許、用量、価格分析
• 臨床試験中のがん抗体薬物複合体：>800以上の薬剤
• 企業別、国別、適応症別、相別のがん抗体薬物複合体の臨床試験インサイト

がん抗体薬物複合体の必要性と当レポートの意義

化学療法や放射線療法などの従来の治療法は、高い毒性を伴うことが多く、正常組織を温存できるような特異性が得られないため、患者にはほとんど、時には厳しい治療の選択肢が残されていません。その結果、効果的で強力な標的がん治療に対する需要はかつてないほど高まっています。この意味で、がん抗体薬物複合体（ADC）は、モノクローナル抗体の選択性と化学療法薬の効能を結びつけ、正常組織への害を抑えながらがん細胞を選択的に死滅させる、がん治療の新たなフロンティアとなります。世界中で20以上の抗体薬物複合体が承認されており、その治療成功はがん治療に革命をもたらしています。

当レポートでは、拡大するがん抗体薬物複合体市場の分析と、現代の腫瘍学においてますます重要な役割を果たす抗体薬物複合体について解説します。また、最近の科学的進歩を記録し、臨床パイプラインの動向をモニターし、将来の商業的および臨床的展望を明らかにすることで、投資家がこのハイリスク・ハイリターンの治療領域をナビゲートするための主な洞察を提供します。

市場機会、承認済みがん抗体薬物複合体の販売、価格設定、投与に関する洞察

当レポートでは、2020年から2025年前半までの承認済みがん抗体薬物複合体20品目の価格、推奨用量、販売データについて詳細な概要を提供しています。当レポートには、販売実績の四半期ごとの内訳とともに、世界および地域別の洞察が含まれています。世界レベルでは、この期間のがん抗体薬物複合体市場の総市場価値を概説し、個々の薬剤が市場全体の数値にどのように寄与しているかを明らかにしています。

報告書に含まれる臨床試験に関する洞察

臨床試験は、固形がんや血液がんなど、さまざまながんの治療における有用性に関する知見を提供し、抗体薬物複合体の開発を支えています。現在、800を超えるがん抗体薬物複合体が、さまざまながん適応症における安全性と有効性の評価、または治療可能な患者集団の拡大を目的として、臨床試験中および承認済みです。例えば、AstraZenecaと第一三共のTROPION試験シリーズは現在、承認用途以外の様々な固形がんを対象にデータポタマブ・デルクステカンを評価しています。GenmabのRAINFOL試験もまた、様々な固形がんにおけるリナタバート・セステカンの可能性を検討しています。これらの試験は、抗体薬物複合体が高いアンメットメディカルニーズにどのように対応できるかを実証する上で極めて重要です。

当レポートでは、主要ながん抗体薬物複合体の臨床試験の詳細な概要に加え、抗体薬物複合体によって試験されている適応症、試験スポンサー、地域情勢別、試験フェーズに関するデータを掲載し、関係者に現在の開発状況を正確に伝えています。これらの見解は、パイプラインの勢いと治療の可能性について常に情報を得る必要のある商業的意思決定者と学術研究者の双方にとって、貴重な備忘録となります。

技術プラットフォーム、共同研究、契約

がん治療用抗体薬物複合体の開発には、がん細胞への細胞毒性ペイロードの標的デリバリーを容易にする技術プラットフォームが不可欠です。その一例として、Daiichi SankyoのDXdプラットフォームは、安定性の向上とペイロード放出の制御により、EnhertuやDatrowayなどの抗体薬物複合体の成功を牽引してきました。

同様に重要なのは、戦略的パートナーシップ、買収候補、ライセンシング契約であり、これらは開発スケジュールを迅速化し、新規ターゲットへのアクセスを増加させ、世界市場への参入を促進します。これらの契約は、がん抗体薬物複合体の技術革新を促進するだけでなく、競争が激化するがん領域でより大きな臨床効果と商業的成功を保証するためにも必要です。

がん抗体薬物複合体の研究開発に関与する主要企業

現在、がん抗体薬物複合体の研究開発の最前線で活躍しているのは、著名な医薬品メーカー数社です。例えば、Pfizerは、抗体薬物複合体技術のリーダーであるシーゲンを買収し、その先進的なプラットフォームとこの分野の専門知識を利用することで、がん治療のポートフォリオを強化しました。AstraZenecaもまた、卵巣がんや乳がんなど、さまざまながんを対象とした候補化合物で、がん抗体薬物複合体のパイプラインを強化しています。有望な抗体薬物複合体MRG003を擁するミラコジェンのような新興バイオテクノロジー企業も、有効性を向上させ副作用を軽減する新技術やデリバリー・メカニズムを中心に、波を起こしています。

当レポートでは、がん抗体薬物複合体のイノベーションを主導する主要企業を、伝統的な製薬企業から新興バイオテクノロジー企業まで、また時折登場するテクノロジープロバイダーも含めて包括的に分析しています。各社の戦略的重点課題、パイプライン開発、標的がん治療の将来を牽引する役割を明らかにしています。

がん抗体薬物複合体セグメントの今後の方向性を強調したレポート

がん抗体薬物複合体の将来は、継続的な技術改良、新たなペイロード、リンカーシステムの改良により有望です。非小細胞肺がんに対するエムレリスやHER2陽性乳がんに対するトラスツズマブ・レゼテカンのように、新たな抗体薬物複合体の承認が続く中、がん領域におけるその可能性はますます高まっています。すでに承認されている治療法に加え、二重特異性抗体薬物複合体や免疫増強抗体薬物複合体などの次世代抗体薬物複合体も、がん治療に革命を起こすと予想されています。これらの治療は、腫瘍の不均一性に対処し、予後を改善することが期待されています。

当レポートでは、科学的動向、規制動向、治療法の進歩を分析することで、がん抗体薬物複合体産業の今後の方向性を検討し、将来の展望を示しています。固形がんと血液がんの両方において抗体薬物複合体の臨床的可能性を最大限に引き出すためには、バイオマーカー主導の戦略、個別化投与、トランスレーショナル・トライアル・デザインの必要性を強調しています。

目次

第1章 調査手法

第2章 抗体薬物複合体のイントロダクション

• 概要
• 抗体薬物複合体のメカニズム

第3章 がん標的治療としての抗体薬物複合体

• がんにおける抗体薬物複合体の応用
• 抗体薬物複合体の利点
• 抗体薬物複合体と従来の治療法の比較

第4章 抗体薬物複合体の世代

• 抗体薬物複合体- 進化
• 次世代抗体薬物複合体の展望

第5章 ブランド名、会社名、適応症別に見た市販承認抗体薬物複合体

第6章 世界のがん抗体薬物複合体市場の展望

• 現在の市場シナリオ
• 将来の成長の道

第7章 世界のがん抗体薬物複合体の調査と市場動向（地域別）

• 米国
• 中国
• 欧州
• 韓国
• オーストラリア
• 英国
• カナダ
• 日本
• インド
• ラテンアメリカ

第8章 世界のがん抗体薬物複合体市場の動向と適応症別の開発

• 肺がん
• 乳がん
• 白血病
• 卵巣がん
• 消化器がん
• リンパ腫
• 尿路上皮がん
• 子宮頸がん
• 頭頸部がん
• 脳腫瘍
• 前立腺がん
• 膵臓がん
• 皮膚がん
• 食道がん

第9章 企業別がん抗体薬物複合体開発プラットフォーム

第10章 承認済みがん抗体薬物複合体- 特許、投与量、価格分析

本章では、承認済みの20種類のがん抗体薬物複合体について、特許、投与量、価格分析に関する包括的な考察を提供します。参考までにいくつかの薬物複合体の名称を記載しており、詳細な分析はサンプルとレポートに含まれています。

• ミロターグ
• アドセトリス
• カドシラ
• ベスポンサ
• ルモキシティ（2023年市場撤退）
• ポリヴィ

第11章 承認済みがん抗体薬物複合体：2020年～2025年の販売動向

• アドセトリス
• パドチェフ
• ティブダク
• ポリヴィ
• カドシラ
• ベスポンサ
• エンヘルトゥ
• トロデルヴィ
• ジンロンタ
• エラヘレ
• ブレンレップ
• ダトロウェイ

第12章 企業、国、適応症、相別の世界がん抗体薬物複合体臨床試験の洞察

• 研究
• 前臨床
• 第I相
• 第I/II相
• 第II相
• 第II/III相
• 第III相
• 事前登録
• 登録

第13章 市販されているがん抗体薬物複合体の臨床試験：企業、国、適応症、相別

第14章 がん抗体薬物複合体の併用療法

第15章 世界のがん抗体薬物複合体市場概要

第16章 競合情勢

• ADC Therapeutics
• Affinity Biopharma
• AstraZeneca
• Biocytogen
• Biokin
• Bristol Myers Squibb
• Daiichi Sankyo
• Duality Biologics
• Eli Lilly
• Immunogen
• Innovent Biologics
• LigaChem Biosciences
• Merck
• Pfizer
• Synaffix

List of Figures

• Figure 2-1: Antibody Drug Conjugates - General Working Mechanism
• Figure 3-1: Advantages of Antibody Drug Conjugates
• Figure 4-1: Antibody-Drug Conjugates - Approval by Generation
• Figure 4-2: Cancer Antibody Drug Conjugates - Opportunities for Next-Generation Development
• Figure 6-1: Global - Cancer Antibody Drug Conjugates Market (US$ Million), 2020-2025
• Figure 6-2: Global -Cancer Antibody Drug Conjugate Sales by Drug (US$ Million), H1'2025
• Figure 6-3: Global - Cancer Antibody Drug Conjugate Sales by Drug (US$ Million), 2024
• Figure 6-4: Global - Cancer Antibody Drug Conjugate Market Share by Drugs (%), 2024
• Figure 6-5: Global - Cancer Antibody Drug Conjugate Market (US$ Million), Q1-Q4'2024
• Figure 6-6: Global - Cancer Antibody Drug Conjugate Market by Drug (US$ Million), 2023
• Figure 6-7: Global - Cancer Antibody Drug Conjugate Market Share by Drugs (%), 2023
• Figure 6-8: Global - Cancer Antibody Drug Conjugate Market Forecast (US$ Billion), 2025 - 2031
• Figure 7-1: Daiichi Sankyo DXd ADC Technology - Clinical Candidates
• Figure 7-2: India - Branded v/s Biosimilar Trastuzumab Emtansine Price by Supply (US$), August'2025
• Figure 8-1: REFRaME-L1 Phase 2 (NCT06555263) Study - Initiation & Completion Year
• Figure 8-2: IDeate-Lung02 Phase 3 (NCT06203210) Study - Initiation & Completion Year
• Figure 8-3: SGNB6A-001 Phase 1 (NCT04389632) Study - Initiation & Completion Year
• Figure 8-4: SGNB6A-002 Phase 3 (NCT06012435) Study - Initiation & Completion Year
• Figure 8-5: MK-2870-004 Phase 3 (NCT06074588) Study - Initiation & Completion Year
• Figure 8-6: SHR-4849-101 Phase 1 (NCT06443489) Study - Initiation & Completion Year
• Figure 8-7: D926QC00001 Phase 3 (NCT06112379) Study - Initiation & Completion Year
• Figure 8-8: TQB2102-III-01 Phase 3 (NCT06561607) Study - Initiation & Completion Year
• Figure 8-9: IZABRIGHT-Breast01 Phase 2/3 (NCT06926868) Study - Initiation & Completion Year
• Figure 8-10: STARt-002 Phase 1/2 (NCT06827613) Study - Initiation & Completion Year
• Figure 8-11: CA235-0001 Phase 1 (NCT06419634) Study - Initiation & Completion Year
• Figure 8-12: VNC-943-101 Phase 1 (NCT06034275) Study - Initiation & Completion Year
• Figure 8-13: RAINFOL-02 Phase 3 (NCT06619236) Study - Initiation & Completion Year
• Figure 8-14: RAINFOL-01 Phase 1/2 (NCT05579366) Study - Initiation & Completion Year
• Figure 8-15: DS6000-109 Phase 2/3 (NCT06161025) Study - Initiation & Completion Year
• Figure 8-16: FONTANA Phase 1/2 (NCT05797168) Study - Initiation & Completion Year
• Figure 8-17: LOXO-FRA-24001 Phase 1 (NCT06400472) Study - Initiation & Completion Year
• Figure 8-18: M24-427 Phase 1 (NCT06084481) Study - Initiation & Completion Year
• Figure 8-19: CUSP06-1001 Phase 1 (NCT06234423) Study - Initiation & Completion Year
• Figure 8-20: TROPION-PanTumor03 Phase 2 (NCT05489211) Study - Initiation & Completion Year
• Figure 8-21: IKS014-01 Phase 1 (NCT05872295) Study - Initiation & Completion Year
• Figure 8-22: D9800C00001 Phase 2 (NCT06219941) Study - Initiation & Completion Year
• Figure 8-23: PROCEADE-PanTumor Phase 1/2 (NCT06710132) Study - Initiation & Completion Year
• Figure 8-24: CIBI343A101 Phase 1 (NCT05458219) Study - Initiation & Completion Year
• Figure 8-25: CTMX-2051-101 Phase 2 (NCT06265688) Study - Initiation & Completion Year
• Figure 8-26: M21-404 Phase 1 (NCT05029882) Study - Initiation & Completion Year
• Figure 8-27: EBC-129-01 Phase 1 (NCT05701527) Study - Initiation & Completion Year
• Figure 8-28: ADRX-0405-001 Phase 1 (NCT06710379) Study - Initiation & Completion Year
• Figure 8-29: Polatuzumab Vedotin Phase 2 (NCT05410418) Study - Initiation & Completion Year
• Figure 8-30: RG1122400 Phase 2 (NCT05453396) Study - Initiation & Completion Year
• Figure 8-31: Blenrep Phase 2 (NCT04676360) Study - Initiation & Completion Year
• Figure 8-32: Blenrep Phase 2 (NCT04676360) Study - Initiation & Completion Year
• Figure 8-33: waveLINE-003 Phase 2/3 (NCT05139017) Study - Initiation & Completion Year
• Figure 8-34: waveLINE-010 Phase 3 (NCT06717347) Study - Initiation & Completion Year
• Figure 8-35: waveLINE-007 Phase 2 (NCT05406401) Study - Initiation & Completion Year
• Figure 8-36: waveLINE-006 Phase 2 (NCT05458297) Study - Initiation & Completion Year
• Figure 8-37: SUNMO Phase 3 (NCT05171647) Study - Initiation & Completion Year
• Figure 8-38: NCI-2023-00999 Phase 2 (NCT05775471) Study - Initiation & Completion Year
• Figure 8-39: RG1122399 Phase 2 (NCT05581589) Study - Initiation & Completion Year
• Figure 8-40: BL-B01D1 Phase 2 (NCT05785039) Study - Initiation & Completion Year
• Figure 8-41: 9MW2821-2023-CP301 Phase 3 (NCT06196736) Study - Initiation & Completion Year
• Figure 8-42: IDE397-001 Phase 1/2 (NCT04794699) Study - Initiation & Completion Year
• Figure 8-43: ADCE-T02-01 Phase 1 (NCT06597721) Study - Initiation & Completion Year
• Figure 8-44: 2000023639 Phase 2 (NCT05838521) Study - Initiation & Completion Year
• Figure 8-45: DESTINY-PanTumor02 Phase 2 (NCT04482309) Study - Initiation & Completion Year
• Figure 8-46: 9MW2821-2021-CP102 Phase 1/2 (NCT05216965) Study - Initiation & Completion Year
• Figure 8-47: ADRX-0706-001 Phase 1 (NCT06036121) Study - Initiation & Completion Year
• Figure 8-48: CRB-701-01 Phase 1/2 (NCT06265727) Study - Initiation & Completion Year
• Figure 8-49: SGNDV-005 Phase 2 (NCT06003231) Study - Initiation & Completion Year
• Figure 8-50: EV-202 Phase 2 (NCT04225117) Study - Initiation & Completion Year
• Figure 8-51: CRB-701-01 Phase 1/2 (NCT06265727) Study - Initiation & Completion Year
• Figure 8-52: SGNPDL1V-001 Phase 1 (NCT05208762) Study - Initiation & Completion Year
• Figure 8-53: DB-1311-O-1001 Phase 1/2 (NCT05914116) Study - Initiation & Completion Year
• Figure 8-54: IRB-43179 Phase 1/2 (NCT03510208) Study - Initiation & Completion Year
• Figure 8-55: MEDOPP575 Phase 2 (NCT05865990) Study - Initiation & Completion Year
• Figure 8-56: UW18043 Phase 2 (NCT03725761) Study - Initiation & Completion Year
• Figure 8-57: ARTEMIS-003 Phase 2 (NCT06001255) Study - Initiation & Completion Year
• Figure 8-58: NCI-2021-08857 Phase 1b/2 (NCT05011188) Study - Initiation & Completion Year
• Figure 8-59: IDeate-Prostate01 Phase 3 (NCT06925737) Study - Initiation & Completion Year
• Figure 8-60: IDeate-PanTumor01 Phase 1/2 (NCT04145622) Study - Initiation & Completion Year
• Figure 8-61: Pancreatic Ductal Adenocarcinoma - Prevalence Compared to Other Pancreatic Cancer Types
• Figure 8-62: TORL2307ADC-001 Phase 1 (NCT05156866) Study - Initiation & Completion Year
• Figure 8-63: EBC-129-01 Phase 1 (NCT05701527) Study - Initiation & Completion Year
• Figure 8-64: XNW27011-I/II-01 Phase 1/2 (NCT06792435) Study - Initiation & Completion Year
• Figure 8-65: BA3021-001 Phase 1/2 (NCT03504488) Study - Initiation & Completion Year
• Figure 8-66: CP-MGC018-02 Phase 1 (NCT05293496) Study - Initiation & Completion Year
• Figure 8-67: AMT-253-02 Phase 1/2 (NCT06209580) Study - Initiation & Completion Year
• Figure 8-68: SGN35-033 Phase 2 (NCT04609566) Study - Initiation & Completion Year
• Figure 8-69: BrUOG 413 Phase 2 (NCT05480384) Study - Initiation & Completion Year
• Figure 8-70: SYSA1501-010 Phase 1/2 (NCT06577376) Study - Initiation & Completion Year
• Figure 8-71: 202401158MIFD Phase 2 (NCT06329869) Study - Initiation & Completion Year
• Figure 8-72: HS-20093-203 Phase 2 (NCT06112704) Study - Initiation & Completion Year
• Figure 8-73: IDeate-Esophageal01 Phase 2 (NCT06644781) Study - Initiation & Completion Year
• Figure 8-74: BL-B01D1-103 Phase 1 (NCT05262491) Study - Initiation & Completion Year
• Figure 8-75: IPH4502-101 Phase 1 (NCT06781983) Study - Initiation & Completion Year
• Figure 8-76: 9MW2821-2021-CP102 Phase 1 (NCT05216965) Study - Initiation & Completion Year
• Figure 9-1: Proprietary ADC Technology - Seagen
• Figure 9-2: ALE.P02 & ALE.P03 - Alentis Therapeutics
• Figure 9-3: TRAAC - Tallac Therapeutics
• Figure 9-4: ATAC - Heidelberg Pharma
• Figure 9-5: Tub-tag(R) & P5 - Tubulis
• Figure 10-1: Mylotarg - FDA Approval, Withdrawal & Re-Approval Year
• Figure 10-2: Mylotarg - Approval Year by Region
• Figure 10-3: Mylotarg - Cost of 4.5 mg Supply in US (US$), July'2025
• Figure 10-4: Adcetris - Approval Year by Region
• Figure 10-5: US - Adcetris FDA Approval Year by Indication
• Figure 10-6: Japan - Adcetris PMDA Approval Year by Indication
• Figure 10-7: US - Adcetris Orphan Drug Designation Approval Year by Indication
• Figure 10-8: Adcetris - Patent Expiration by Region
• Figure 10-9: Adcetris - Cost of 50 mg Supply in US (US$), July'2025
• Figure 10-10: US - Kadcyla FDA Approval Year by Indication
• Figure 10-11: Kadcyla - Approval Year by Region
• Figure 10-12: US - Kadcyla FDA Approval & Patent Expiration Year
• Figure 10-13: Kadcyla - Cost of Supply in US & Europe (US$), July'2025
• Figure 10-14: Kadcyla - Recommended Dose after 1st & 2nd Dose Reduction (mg/kg)
• Figure 10-15: Besponsa - Approval Year by Region
• Figure 10-16: Besponsa - Cost of 0.9 mg Supply in US & 1 mg Supply in Europe, July'2025
• Figure 10-17: Lumoxiti - Orphan Designation Years
• Figure 10-18: Lumoxiti - Patent Expiry Years
• Figure 10-19: Lumoxiti - Cost of 1 mg Supply in US (US$), July'2025
• Figure 10-20: Lumoxiti - Cost of 1 mg Supply in US & Europe (US$), July'2025
• Figure 10-21: Polivy - Approval Year by Region
• Figure 10-22: Polivy - Orphan Drug Designation Approval Year by Region
• Figure 10-23: US - Polivy Orphan Drug Designation Approval & Exclusivity Year
• Figure 10-24: Polivy - Cost of Supply in US & Europe (US$), July'2025
• Figure 10-25: Padcev - Approval Year by Region
• Figure 10-26: US - Padcev FDA Approval & Patent Expiration Year
• Figure 10-27: Padcev - Cost of Supply In US & Europe (US$), July'2025
• Figure 10-28: Enhertu - Approval Year by Region
• Figure 10-29: US - Polivy FDA Approval Year by Indication
• Figure 10-30: Enhertu - FDA Orphan Drug Designation & Exclusivity Expiration Year
• Figure 10-31: Enhertu - Cost of 100 mg Supply In US & Europe (US$), July'2025
• Figure 10-32: US - Trodelvy FDA Approval by Indication
• Figure 10-33: Trodelvy - Approval Year by Region
• Figure 10-34: Trodelvy - Patent Expiration by Region
• Figure 10-35: Trodelvy - Cost of Supply In US & Europe (US$), July'2025
• Figure 10-36: Blenrep - FDA & EMA Orphan Drug Designations
• Figure 10-37: Blenrep - FDA & EMA Approval
• Figure 10-38: Zynlonta - FDA & EMA Approval Years
• Figure 10-39: Zynlonta - FDA & EMA Orphan Drug Designation Years
• Figure 10-40: Zynlonta - Cost of 10 mg Supply In US & Europe (US$), July'2025
• Figure 10-41: Tivdak - Cost of 40 mg Supply Europe (US$), July'2025
• Figure 10-42: Ujvira - Cost of 100 mg & 160 mg Supply in India (US$), July'2025
• Figure 10-43: Akalux - Sakigake Designation & PMDA Approval Year
• Figure 10-44: Aidixi - China Approval Year & FDA Breakthrough Therapy Designation Year
• Figure 10-45: Datroway - Cost of 100 mg Supply In US & Europe (US$), July'2025
• Figure 11-1: Adcetris - Global Annual Sales (US$ Million), 2020-2025
• Figure 11-2: Adcetris - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 11-3: Adcetris - Global Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 11-4: Padcev - Global Annual Sales (US$ Million), 2020-2025
• Figure 11-5: Padcev - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 11-6: Padcev - Global Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 11-7: Tivdak - Global Annual Sales (US$ Million), 2021-2025
• Figure 11-8: Tivdak - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 11-9: Tivdak - Global Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 11-10: Polivy - Global Sales Values (US$ Million), 2020-2025
• Figure 11-11: Polivy - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2025
• Figure 11-12: Polivy - Global Sales By Region (%), H1'2025
• Figure 11-13: Polivy - Global Quarterly Sales Values (US$ Million), Q1-Q4'2024
• Figure 11-14: Polivy - Global Sales By Region (US$ Million), 2024
• Figure 11-15: Polivy - Global Sales By Region (%), 2024
• Figure 11-16: Polivy - US Annual Sales Values (US$ Million), 2020-2025
• Figure 11-17: Polivy - US Quarterly Sales Values (US$ Million), Q1 & Q2'2025
• Figure 11-18: Polivy - US Quarterly Sales Values (US$ Million), Q1-Q4'2024
• Figure 11-19: Polivy - Europe Annual Sales Values (US$ Million), 2020-2025
• Figure 11-20: Polivy - Europe Quarterly Sales Values (US$ Million), Q1 & Q2'2025
• Figure 11-21: Polivy - Europe Quarterly Sales Values (US$ Million), Q1-Q4'2024
• Figure 11-22: Polivy - Japan Annual Sales Values (US$ Million), 2020-2025
• Figure 11-23: Polivy - Japan Quarterly Sales Values (US$ Million), Q1 & Q2'2025
• Figure 11-24: Polivy - Japan Quarterly Sales Values (US$ Million), Q1-Q4'2024
• Figure 11-25: Polivy - ROW Annual Sales Values (US$ Million), 2020-2025
• Figure 11-26: Polivy - ROW Quarterly Sales Values (US$ Million), Q1 & Q2'2025
• Figure 11-27: Polivy - ROW Quarterly Sales Values (US$ Million), Q1-Q4'2024
• Figure 11-28: Kadcyla - Global Sales Values (US$ Million), 2020-2025
• Figure 11-29: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2025
• Figure 11-30: Kadcyla - Global Sales By Region (%), H1'2025
• Figure 11-31: Kadcyla - Global Quarterly Sales Values (US$ Million), Q1-Q4'2024
• Figure 11-32: Kadcyla - Global Sales By Region (US$ Million), 2024
• Figure 11-33: Kadcyla - Global Sales By Region (%), 2024
• Figure 11-34: Kadcyla - US Annual Sales Values (US$ Million), 2020-2025
• Figure 11-35: Kadcyla - US Quarterly Sales Values (US$ Million), Q1 & Q2'2025
• Figure 11-36: Kadcyla - US Quarterly Sales Values (US$ Million), Q1-Q4'2024
• Figure 11-37: Kadcyla - Europe Annual Sales Values (US$ Million), 2020-2025
• Figure 11-38: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1'2025
• Figure 11-39: Kadcyla - Europe Quarterly Sales Values (US$ Million), Q1-Q4'2024
• Figure 11-40: Kadcyla - Japan Annual Sales Values (US$ Million), 2020-2025
• Figure 11-41: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1 & Q2'2025
• Figure 11-42: Kadcyla - Japan Quarterly Sales Values (US$ Million), Q1-Q4'2024
• Figure 11-43: Kadcyla - ROW Annual Sales Values (US$ Million), 2020-2025
• Figure 11-44: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1 & Q2'2025
• Figure 11-45: Kadcyla - ROW Quarterly Sales Values (US$ Million), Q1-Q4'2024
• Figure 11-46: Besponsa - Global Annual Sales (US$ Million), 2020-2023
• Figure 11-47: Besponsa - Global Sales by Region (US$ Million), 2023
• Figure 11-48: Besponsa - Quarterly Sales by Region (%), Q1-Q4'2024
• Figure 11-49: Besponsa - Global Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 11-50: Besponsa - US Annual Sales (US$ Million), 2020-2023
• Figure 11-51: Besponsa - Europe Quarterly Sales (US$ Million), 2022
• Figure 11-52: Besponsa - ROW Quarterly Sales (US$ Million), 2022
• Figure 11-53: Enhertu - Global Annual Sales (US$ Million), 2020-2025
• Figure 11-54: Enhertu - Global Quarterly Sales Values (US$ Million), Q1 & Q2'2025
• Figure 11-55: Enhertu - Global Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 11-56: Trodelvy - Global Annual Sales (US$ Million), 2020-2025
• Figure 11-57: Trodelvy - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 11-58: Trodelvy - Annual Sales By Region (US$ Million), 2025
• Figure 11-59: Trodelvy - Annual Sales By Region (%), 2025
• Figure 11-60: Trodelvy - Global Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 11-61: Trodelvy - Annual Sales By Region (US$ Million), 2024
• Figure 11-62: Trodelvy - Annual Sales By Region (%), 2024
• Figure 11-63: Trodelvy - US Annual Sales (US$ Million), 2020-2025
• Figure 11-64: Trodelvy - US Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 11-65: Trodelvy - US Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 11-66: Trodelvy - Europe Annual Sales (US$ Million), 2020-2025
• Figure 11-67: Trodelvy - Europe Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 11-68: Trodelvy - Europe Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 11-69: Trodelvy - ROW Annual Sales (US$ Million), 2022-2025
• Figure 11-70: Trodelvy - ROW Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 11-71: Trodelvy - ROW Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 11-72: Zynlonta - Global Annual Sales (US$ Million), 2021-2025
• Figure 11-73: Zynlonta - Global Quarterly Sales (US$ Million), Q1 & Q2'2025
• Figure 11-74: Zynlonta - Global Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 11-75: Elahere - Global Annual Sales (US$ Million), 2022-2025
• Figure 11-76: Elahere - Global Quarterly Sales (US$ Million), Q1-Q2'2025
• Figure 11-77: Elahere - Global Quarterly Sales by Region (US$ Million), H2'2025
• Figure 11-78: Elahere - Global Quarterly Sales (US$ Million), Q1-Q4'2024
• Figure 11-79: Blenrep - Global Annual Sales (US$ Million), 2020-2025
• Figure 11-80: Blenrep - Europe Quarterly Sales Value (US$ Million), Q1-Q4'2024
• Figure 11-81: Datroway - Global Annual Sales (US$ Million), 2025
• Figure 12-1: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Phase, 2025 Till 2031
• Figure 14-1: Antibody Drug Conjugate Combinations in Studies
• Figure 14-2: Approved Antibody Drug Conjugate Combinations

List of Tables

• Table 4-1: First Generation Antibody Drug Conjugates - Examples
• Table 4-2: Second Generation Antibody Drug Conjugates - Examples
• Table 4-3: Third Generation Antibody Drug Conjugates - Examples
• Table 4-4: Fourth Generation Antibody Drug Conjugates - Examples
• Table 5-1: Approved Antibody Drug Conjugates, July'2025
• Table 6-1: Cancer Antibody Drug Conjugates - Recent Collaborations
• Table 6-2: Cancer Antibody Drug Conjugates - Companies Securing Funding for Clinical Development
• Table 6-3: Cancer Antibody Drug Conjugates - Recent Regulatory Designations
• Table 6-4: Cancer Antibody Drug Conjugates - Recent IND Clearances
• Table 7-1: US - Approved Cancer Antibody Drug Conjugates, May'2025
• Table 7-2: China - Approved Antibody Drug Conjugates, July'2025
• Table 7-3: EU - Approved Cancer Antibody Drug Conjugates, July'2025
• Table 7-4: Australia - Approved Cancer Antibody Drug Conjugates, July'2025
• Table 7-5: UK - Approved Antibody Drug Conjugates, July'2025
• Table 7-6: Canada - Approved Cancer Antibody Drug Conjugates, July'2025
• Table 7-7: Japan - Approved Cancer Antibody Drug Conjugates, July'2025
• Table 8-1: Lung Cancer - Approved Antibody Drug Conjugates, July'2025
• Table 8-2: Breast Cancer - Approved Antibody Drug Conjugates, July'2025
• Table 8-3: Leukemia - Approved Antibody Drug Conjugates, July'2025
• Table 8-4: Ovarian Cancer - Approved Antibody Drug Conjugate
• Table 8-5: Gastrointestinal Cancer - Approved Antibody Drug Conjugates
• Table 8-6: Lymphoma - Approved Antibody Drug Conjugates
• Table 8-7: Urogenital Cancer - Approved Antibody Drug Conjugates
• Table 8-8: Cervical Cancer - Approved Antibody Drug Conjugates
• Table 8-9: Head & Neck Cancer - Approved Antibody Drug Conjugates
• Table 10-1: Adcetris - Recommended Dosage
• Table 10-2: Datroway - Premedication and Concomitant Medications
• Table 10-3: Datroway - Recommended Dosage Reductions for Adverse Reactions
• Table 10-4: Emrelis: Recommended Dose Reductions
• Table 14-1: Antibody Drug Conjugate Combinations - Ongoing Clinical Trials

Global Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2031 Report Findings & Highlights:

• Global Cancer Antibody Drug Conjugates Market Opportunity: > USD 70 Billion By 2031
• Global & Regional Market Size Insight (Yearly & Quarterly): 2020 Till H1'2025
• Global Cancer Antibody Drug Conjugates Market Forecast: 2026 Till 2031
• Number Of Approved Cancer Antibody Drug Conjugates: > 20 Antibody Drug Conjugates
• Approved Cancer Antibody Drug Conjugates Sales Insight : 2020 Till 2025
• Approved Cancer Antibody Drug Conjugates Patent, Dosage & Price Analysis
• Cancer Antibody Drug Conjugates In Clinical Trials: > 800 Drugs
• Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase

Need For Cancer Antibody Drug Conjugates & Why This Report?

Traditional treatments such as chemotherapy and radiation are frequently associated with high toxicity and fail to provide the specificity that would allow for sparing of normal tissue, so that patients are left with few and sometimes severe treatment options. Consequently, the demand for effective powerful and targeted cancer therapies has never been greater. In this sense, Cancer Antibody Drug Conjugates (ADCs) represent a new frontier in cancer therapy, marrying the selectivity of monoclonal antibodies with the potency of chemotherapy drugs to selectively kill cancer cells while reducing harm to normal tissue. With over 20 antibody drug conjugates approved globally, their therapeutic success is revolutionizing cancer treatment.

This report provides an analysis of the expanding cancer antibody drug conjugates market and its increasingly prominent role in modern oncology. It also records the most recent scientific advances, monitors developments through clinical pipelines, and identifies future commercial and clinical prospects, thus providing key insight for investors to navigate this high-risk, high-reward therapeutic area.

Market Opportunity, Approved Cancer Antibody Drug Conjugates Sales, Pricing, & Dosing Insight

This report provides a detailed overview of pricing, recommended dosing, and sales data for the 20 approved cancer antibody drug conjugates from 2020 to the first half of 2025. It includes both global and regional insights, along with a quarterly breakdown of sales performance. At the global level, the report outlines the total market value of the cancer antibody drug conjugates market over this period and highlights how each individual drug contributes to overall market figures.

Clinical Trials Insight Included In Report

Clinical trials are at the backbone of antibody drug conjugates development, offering insights into their utility in the treatment of a number of cancers, such as solid tumors and blood cancers. Currently, more than 800 cancer antibody drug conjugates both under investigation and approved, are being tested in clinical trials, aimed at evaluating their safety and efficacy in different cancer indications or broadening their treatable patient population. For instance, AstraZeneca and Daiichi Sankyo's TROPION trial series is currently assessing Datopotamab deruxtecan in a variety of solid tumors outside its approved uses. Genmab's RAINFOL trials are also examining the potential of Rinatabart Sesutecan in various solid tumors. These trials are critical in demonstrating how antibody drug conjugates can address high, unmet medical needs

The report contains an in-depth overview of key cancer antibody drug conjugates clinical trials, along with data on indications being tested by antibody drug conjugates, the trial sponsors, geographic regions and trial phases, providing stakeholders with an accurate picture of the development landscape at present. These observations are a valuable reminder for both commercial decision-makers and academic researchers who need to stay informed of pipeline momentum and therapeutic potential.

Technology Platforms, Collaborations & Agreements

Technology platforms are crucial to the development of antibody drug conjugates for cancer treatment, facilitating targeted delivery of cytotoxic payload to cancer cells. To illustrate this, Daiichi Sankyo's DXd platform has driven the success of antibody drug conjugates such as Enhertu and Datroway, with improved stability and controlled payload release.

Equally important are strategic partnerships, candidate acquisitions and licensing deals, that expedite development timelines, increase access to new targets, and fuel global market reach. These agreements are necessary not only to promote cancer antibody drug conjugates innovation but also to guarantee greater clinical impact and commercial success in an increasingly competitive oncology landscape.

Key Companies Involved in R&D of Cancer Antibody Drug Conjugates

Several prominent drug makers are now active at the forefront of cancer antibody drug conjugates research and development. For instance, Pfizer has enhanced its cancer treatment portfolio by acquiring Seagen, a leader in antibody drug conjugates technology, gaining access to its advanced platform and expertise in the field. AstraZeneca has also strengthened its cancer antibody drug conjugates pipeline, with candidates aiming at a range of cancers, such as ovarian and breast cancers. Emerging biotech firms like Miracogen, with its promising antibody drug conjugates MRG003, are also making waves, centering on new technologies and delivery mechanisms to improve efficacy and reduce side effects.

This report presents a comprehensive analysis of the companies leading cancer antibody drug conjugates innovation, ranging from the traditional pharmaceutical powerhouses to the new biotech upstarts, as well as the occasional technology providers. It identifies each company's strategic emphasis, pipeline development, and role in driving the future of targeted cancer treatment.

Report Highlighting Future Direction of Cancer Antibody Drug Conjugates Segment

The future of cancer antibody drug conjugates is promising, with ongoing technology improvement, new payloads, and improved linker systems. As new antibody drug conjugates continue receiving approval, like Emrelis for non-small cell lung cancer and Trastuzumab rezetecan for HER2-positive breast cancer, their potential in oncology are increasing. Besides those therapies already approved, next-generation antibody drug conjugates, including bispecific antibody drug conjugates and immune-enhancing antibody drug conjugates, are also anticipated to revolutionize cancer therapy. These treatments hold the promise of addressing tumor heterogeneity and enhancing outcome.

Providing a vision of the future, this report examines the future direction of the cancer antibody drug conjugates industry, with analysis of scientific trends, regulatory trends, and therapeutic advances. It highlights the need for biomarker-driven strategies, individualized dosing, and translational trial design in order to realize the maximum clinical potential of antibody drug conjugates in both solid tumors and hematological cancers.

Table of Contents

1. RESEARCH METHODOLOGY

2. Introduction To Antibody Drug Conjugates

• 2.1 Overview
• 2.2 Mechanism of Antibody Drug Conjugates

3. Antibody Drug Conjugates As Cancer Targeted Therapy

• 3.1 Applications of Antibody Drug Conjugates in Cancer
• 3.2 Advantages of Antibody Drug Conjugates
• 3.3 Comparison of Antibody Drug Conjugates With Traditional Therapies

4. Generations of Antibody Drug Conjugates

• 4.1 Antibody Drug Conjugates - Evolution
• 4.2 Next Generation Antibody Drug Conjugates Prospects

5. Commercially Approved Antibody Drug Conjugates By Brand Name, Company & Indication

6. Global Cancer Antibody Drug Conjugates Market Outlook

• 6.1 Current Market Scenario
• 6.2 Future Growth Avenues

7. Global Cancer Antibody Drug Conjugates Research & Market Trends by Region

• 7.1 US
• 7.2 China
• 7.3 Europe
• 7.4 South Korea
• 7.5 Australia
• 7.6 UK
• 7.7 Canada
• 7.8 Japan
• 7.9 India
• 7.10 Latin America

8. Global Cancer Antibody Drug Conjugates Market Trends & Development By Indications

• 8.1 Lung Cancer
• 8.2 Breast cancer
• 8.3 Leukemia
• 8.4 Ovarian Cancer
• 8.5 Gastrointestinal Cancers
• 8.6 Lymphoma
• 8.7 Urothelial Carcinoma
• 8.8 Cervical Cancer
• 8.9 Head & Neck Cancer
• 8.10 Brain Cancer
• 8.11 Prostate cancer
• 8.12 Pancreatic Cancer
• 8.13 Skin cancer
• 8.14 Esophageal cancer

9. Cancer Antibody Drug Conjugates Development Platforms By Company

10. Approved Cancer Antibody Drug Conjugates - Patent, Dosage & Price Analysis

This Chapter Gives Comprehensive Insight On Patent, Dosage & Price Analysis For 20 Approved Cancer Antibody Drug Conjugates. We Have Mentioned Few Drug Conjugates Names For Reference, Detailed Insight Included In Sample & Report

• 10.1 Mylotarg
  • 10.1.1 Overview, Availability & Patent Insight
  • 10.1.2 Pricing & Dosage Insight
• 10.2 Adcetris
  • 10.2.1 Overview, Availability & Patent Insight
  • 10.2.2 Pricing & Dosage Insight
• 10.3 Kadcyla
  • 10.3.1 Overview, Availability & Patent Insight
  • 10.3.2 Pricing & Dosage Insight
• 10.4 Besponsa
  • 10.4.1 Overview & Availability Insight
  • 10.4.2 Pricing & Dosage Insight
• 10.5 Lumoxiti (Market Withdrawal In 2023)
  • 10.5.1 Overview, Availability & Patent Insight
  • 10.5.2 Pricing & Dosage Insight
• 10.6 Polivy
  • 10.6.1 Overview, Availability & Patent Insight
  • 10.6.2 Pricing & Dosage Insight

11. Approved Cancer Antibody Drug Conjugates - Sales Insights 2020 - 2025

• 11.1 Adcetris
• 11.2 Padcev
• 11.3 Tivdak
• 11.4 Polivy
• 11.5 Kadcyla
• 11.6 Besponsa
• 11.7 Enhertu
• 11.8 Trodelvy
• 11.9 Zynlonta
• 11.10 Elahere
• 11.11 Blenrep
• 11.12 Datroway

12. Global Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

• 12.1 Research
• 12.2 Preclinical
• 12.3 Phase I
• 12.4 Phase I/II
• 12.5 Phase II
• 12.6 Phase II/III
• 12.7 Phase III
• 12.8 Preregistration
• 12.9 Registration

13. Marketed Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

14. Cancer Antibody Drug Conjugates Combination Therapies

15. Global Cancer Antibody Drug Conjugates Market Overview

• 15.1 Key Market Growth Drivers
• 15.2 Challenges For Market Growth

16. Competitive Landscape

• 16.1 ADC Therapeutics
• 16.2 Affinity Biopharma
• 16.3 AstraZeneca
• 16.4 Biocytogen
• 16.5 Biokin
• 16.6 Bristol Myers Squibb
• 16.7 Daiichi Sankyo
• 16.8 Duality Biologics
• 16.9 Eli Lilly
• 16.10 Immunogen
• 16.11 Innovent Biologics
• 16.12 LigaChem Biosciences
• 16.13 Merck
• 16.14 Pfizer
• 16.15 Synaffix